Short answer
Fulcrum Therapeutics, Inc. (FULC) filed its Q1 2026 10-Q quarterly report on Apr 27, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$19M
- −7.0% YoY
- EPS (diluted)
- −$0.25
- +10.7% YoY
Source: XBRL data from the Fulcrum Therapeutics, Inc. (FULC) Q1 2026 10-Q on SEC EDGAR. USD.
Fulcrum Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales generated
- Net loss $18.9M vs $17.7M YoY; operating loss $22.2M vs $20.4M
- Pociredir external R&D $5.4M vs $4.3M; losmapimod $0 vs $1.0M
- Cash, equivalents and securities $333.3M; operating cash use $18.8M vs $15.3M
- Cash runway into 2029; registration-enabling trial planned for second half of 2026
Risk Factors
- Newly highlighted tax risk from July 2025 OBBBA, which could materially affect future cash flow, financial condition, or results
- Most material funding risk: $333.3 million liquidity projected through 2029, subject to potentially incorrect operating assumptions
- Regulatory risk: additional FDA-required studies or clinical holds could delay pociredir development and increase expenses
- Operational risk: pociredir is the only product candidate in active clinical development after losmapimod’s Phase 3 failure
- Financial concentration: federal NOL carryforwards of $102.8 million limited to 80% of annual taxable income
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulcrum Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.